Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.59 |
| ▸ | CRHBP | P24387 | 1/20 | 0.59 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.59 |
| ▸ | PPARD | Q03181 | 8/20 | 0.49 |
| ▸ | PPARA | Q07869 | 6/20 | 0.49 |
| ▸ | PPARG | P37231 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4906319 | 0.89 | MAPT (0.49) | MEN1MAPTKMT2AKDM4EHSP90AA1 | |
| SCHEMBL4473367 | 0.88 | MAPT (0.57) | MEN1MAPTKMT2AKDM4EHSP90AA1 | |
| SCHEMBL6604649 | 0.86 | TRPM8 (0.56) | MEN1MAPTKMT2APPARAPPARG | |
| SCHEMBL4899851 | 0.86 | LMNA (0.47) | MEN1MAPTKMT2AKDM4EHSP90AA1 | |
| SCHEMBL4905523 | 0.84 | MAPT (0.56) | MEN1MAPTKMT2AKDM4ENPC1 | |
| SCHEMBL14573031 | 0.83 | PPARD (0.63) | MEN1MAPTKMT2AKDM4EHSP90AA1 | |
| SCHEMBL3534461 | 0.83 | TRPM8 (0.47) | MEN1MAPTKMT2AKDM4EHSP90AA1 | |
| SCHEMBL27689187 | 0.81 | MAPT (0.53) | MEN1MAPTKMT2AKDM4EHSP90AA1 | |
| SCHEMBL18015833 | 0.80 | MAPT (0.50) | MEN1MAPTKMT2AKDM4EHSP90AA1 | |
| SCHEMBL20642209 | 0.80 | MAPT (0.68) | MEN1MAPTKMT2AKDM4EHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7872032-B2 | 1, 3, 4-oxadiazol-2-ones as PPAR delta modulators and their use thereof | AVENTIS PARMACEUTICALS INC. (US) | 2011-01-18 | — | — | US | disclosed |
| US-7872032-B2 | 1, 3, 4-oxadiazol-2-ones as PPAR delta modulators and their use thereof | AVENTIS PARMACEUTICALS INC. (US) | 2011-01-18 | — | — | US | disclosed |
| US-7872032-B2 | 1, 3, 4-oxadiazol-2-ones as PPAR delta modulators and their use thereof | AVENTIS PARMACEUTICALS INC. (US) | 2011-01-18 | — | — | US | disclosed |
| US-7638539-B2 | 1, 3, 4-oxadiazol-2-ones as peroxisome-proliferator activated receptor delta modulators and their use in the treatment of neurological and metabolic disease | AVENTIS PHARMACEUTICALS INC. (US) | 2009-12-29 | — | — | US | disclosed |
| US-7638539-B2 | 1, 3, 4-oxadiazol-2-ones as peroxisome-proliferator activated receptor delta modulators and their use in the treatment of neurological and metabolic disease | AVENTIS PHARMACEUTICALS INC. (US) | 2009-12-29 | — | — | US | disclosed |
| US-7638539-B2 | 1, 3, 4-oxadiazol-2-ones as peroxisome-proliferator activated receptor delta modulators and their use in the treatment of neurological and metabolic disease | AVENTIS PHARMACEUTICALS INC. (US) | 2009-12-29 | — | — | US | disclosed |
| US-20090275621-A1 | 1, 3, 4-OXADIAZOL-2-ONES AS PPAR DELTA MODULATORS AND THEIR USE THEREOF | AVENTIS PHARMACEUTICALS INC. (US) | 2009-11-05 | — | — | US | disclosed |
| US-20090275621-A1 | 1, 3, 4-OXADIAZOL-2-ONES AS PPAR DELTA MODULATORS AND THEIR USE THEREOF | AVENTIS PHARMACEUTICALS INC. (US) | 2009-11-05 | — | — | US | disclosed |
| US-20090275621-A1 | 1, 3, 4-OXADIAZOL-2-ONES AS PPAR DELTA MODULATORS AND THEIR USE THEREOF | AVENTIS PHARMACEUTICALS INC. (US) | 2009-11-05 | — | — | US | disclosed |
| CN-101287718-A | Substituted heteroaryl- and phenylsulfamoyl compounds | PFIZER PROD INC (US) | 2008-10-15 | — | — | CN | disclosed |
| US-20080090829-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PFIZER INC. | 2008-04-17 | — | — | US | disclosed |
| EP-1781648-A2 | 1,3,4-OXADIAZOL-2-ONES AS PPAR DELTA MODULATORS | Aventis Pharmaceuticals Inc. (US) | 2007-05-09 | — | — | EP | disclosed |
| US-20070099964-A1 | 1, 3, 4-OXADIAZOL-2-ONES AS PEROXISOME-PROLIFERATOR ACTIVATED RECEPTOR DELTA MODULATORS AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL AND METABOLIC DISEASE | AVENTIS PHARMACEUTICALS INC. (US) | 2007-05-03 | — | — | US | disclosed |
| US-20070099964-A1 | 1, 3, 4-OXADIAZOL-2-ONES AS PEROXISOME-PROLIFERATOR ACTIVATED RECEPTOR DELTA MODULATORS AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL AND METABOLIC DISEASE | AVENTIS PHARMACEUTICALS INC. (US) | 2007-05-03 | — | — | US | disclosed |
| US-20070099964-A1 | 1, 3, 4-OXADIAZOL-2-ONES AS PEROXISOME-PROLIFERATOR ACTIVATED RECEPTOR DELTA MODULATORS AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL AND METABOLIC DISEASE | AVENTIS PHARMACEUTICALS INC. (US) | 2007-05-03 | — | — | US | disclosed |
| EP-1765796-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | Pfizer Products Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20060229363-A1 | Substituted Heteroaryl- and Phenylsulfamoyl Compounds | HAMANAKA ERNEST S | 2006-10-12 | — | — | US | disclosed |
| WO-2006003495-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2006-01-12 | — | — | WO | disclosed |
| US-20050288340-A1 | Substituted heteroaryl- and phenylsulfamoyl compounds | PFIZER INC | 2005-12-29 | — | — | US | disclosed |
| WO-2005097763-A2 | 1,3,4-OXADIAZOL-2-ONES AS PPAR DELTA | AVENTIS PHARMACEUTICALS INC. (US) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229363-A1 | Substituted Heteroaryl- and Phenylsulfamoyl Compounds | PPARA, PPARG, PPARD | MEN1 4859/4885MAPT 1858/4885KMT2A 3602/4885 |
| US-20050288340-A1 | Substituted heteroaryl- and phenylsulfamoyl compounds | PPARA, PPARG, PPARD | MEN1 4855/4885MAPT 1786/4885KMT2A 3530/4885 |
| US-20090275621-A1 | 1, 3, 4-OXADIAZOL-2-ONES AS PPAR DELTA MODULATORS AND THEIR USE THEREOF | PPARD, PPARA, PPARG | MEN1 4789/4885MAPT 487/4885KMT2A 4308/4885 |
| US-20070099964-A1 | 1, 3, 4-OXADIAZOL-2-ONES AS PEROXISOME-PROLIFERATOR ACTIVATED RECEPTOR DELTA MODULATORS AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL AND METABOLIC DISEASE | PPARD, PPARA, PPARG | MEN1 4508/4885MAPT 338/4885KMT2A 3738/4885 |
| US-20080090829-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PPARA, PPARG, PPARD | MEN1 4855/4885MAPT 1786/4885KMT2A 3530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.